CStone Pharmaceuticals
HKEX:2616
CStone Pharmaceuticals
HKEX:2616
Price:
10.18
HKD
0.79%
Market Closed
Market Cap:
HK$15B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
CStone Pharmaceuticals
HKEX:2616
|
CN |
|
M
|
Mce Holdings Bhd
KLSE:MCEHLDG
|
MY |
|
Applovin Corp
NASDAQ:APP
|
US |
|
Shentong Robot Education Group Co Ltd
HKEX:8206
|
HK |
Income Statement
Earnings Waterfall
CStone Pharmaceuticals
CStone Pharmaceuticals
Income Statement
CStone Pharmaceuticals
CStone Pharmaceuticals
Currency: CNY
| Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
1
|
0
|
2
|
0
|
8
|
0
|
10
|
0
|
12
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1 039
N/A
|
1 118
+8%
|
244
-78%
|
426
+75%
|
481
+13%
|
481
0%
|
464
-4%
|
457
-2%
|
407
-11%
|
202
-50%
|
270
+33%
|
|
| Gross Profit | ||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
(241)
|
(273)
|
(107)
|
(168)
|
(203)
|
(218)
|
(160)
|
(134)
|
(167)
|
(227)
|
(218)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
797
N/A
|
846
+6%
|
137
-84%
|
258
+88%
|
278
+8%
|
263
-6%
|
304
+16%
|
323
+6%
|
240
-26%
|
(25)
N/A
|
51
N/A
|
|
| Operating Income | ||||||||||||||||
| Operating Expenses |
(1 017)
|
(1 018)
|
(1 713)
|
(1 892)
|
(1 860)
|
(1 931)
|
(1 930)
|
(1 679)
|
(1 158)
|
(1 029)
|
(858)
|
(631)
|
(322)
|
(330)
|
(442)
|
|
| Selling, General & Administrative |
(191)
|
(322)
|
(341)
|
(363)
|
(485)
|
(583)
|
(661)
|
(655)
|
(576)
|
(516)
|
(382)
|
(271)
|
(212)
|
(181)
|
(172)
|
|
| Research & Development |
(850)
|
0
|
(1 396)
|
(1 556)
|
(1 405)
|
(1 373)
|
(1 305)
|
(1 059)
|
(591)
|
(529)
|
(501)
|
(382)
|
(124)
|
(163)
|
(295)
|
|
| Other Operating Expenses |
24
|
(697)
|
24
|
27
|
30
|
25
|
36
|
35
|
9
|
15
|
26
|
23
|
13
|
14
|
26
|
|
| Operating Income |
(1 017)
N/A
|
(1 018)
0%
|
(1 713)
-68%
|
(1 892)
-10%
|
(1 062)
+44%
|
(1 086)
-2%
|
(1 793)
-65%
|
(1 421)
+21%
|
(880)
+38%
|
(767)
+13%
|
(553)
+28%
|
(308)
+44%
|
(82)
+73%
|
(354)
-333%
|
(390)
-10%
|
|
| Pre-Tax Income | ||||||||||||||||
| Interest Income Expense |
(746)
|
(1 218)
|
(578)
|
148
|
(159)
|
(238)
|
(126)
|
(86)
|
1
|
22
|
35
|
11
|
4
|
(12)
|
(14)
|
|
| Non-Reccuring Items |
(30)
|
(48)
|
(18)
|
(0)
|
0
|
0
|
(1)
|
0
|
(23)
|
(6)
|
152
|
154
|
(10)
|
(11)
|
(20)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
(3)
|
0
|
0
|
|
| Pre-Tax Income |
(1 793)
N/A
|
(2 285)
-27%
|
(2 308)
-1%
|
(1 744)
+24%
|
(1 221)
+30%
|
(1 324)
-8%
|
(1 920)
-45%
|
(1 508)
+21%
|
(903)
+40%
|
(750)
+17%
|
(367)
+51%
|
(142)
+61%
|
(91)
+36%
|
(377)
-313%
|
(424)
-12%
|
|
| Net Income | ||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(13)
|
|
| Income from Continuing Operations |
(1 793)
|
(2 285)
|
(2 308)
|
(1 744)
|
(1 221)
|
(1 324)
|
(1 920)
|
(1 508)
|
(903)
|
(750)
|
(367)
|
(142)
|
(91)
|
(377)
|
(437)
|
|
| Income to Minority Interest |
48
|
21
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(470)
N/A
|
(1 246)
-165%
|
(2 069)
-66%
|
(1 744)
+16%
|
(1 221)
+30%
|
(1 324)
-8%
|
(1 920)
-45%
|
(1 508)
+21%
|
(903)
+40%
|
(750)
+17%
|
(367)
+51%
|
(142)
+61%
|
(91)
+36%
|
(377)
-313%
|
(437)
-16%
|
|
| EPS (Diluted) |
-2.79
N/A
|
-1.68
+40%
|
-2.39
-42%
|
-1.74
+27%
|
-1.17
+33%
|
-1.14
+3%
|
-1.65
-45%
|
-1.28
+22%
|
-0.77
+40%
|
-0.59
+23%
|
-0.29
+51%
|
-0.11
+62%
|
-0.07
+36%
|
-0.29
-314%
|
-0.31
-7%
|
|
Switch to:
Switch to:
See Also
Discover More
